查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
心臟安全服務市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)
市場調查報告書
商品編碼
1190226

心臟安全服務市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Cardiac Safety Service Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計心臟安全服務市場在預測期內（2022 年至 2027 年）的複合年增長率為 9%。

COVID-19 大流行給醫療保健行業帶來了巨大壓力，使其更加註重提供更好的醫療設施、監測設備、服務和遠程會診。 根據世界衛生組織 (WHO) 2020 年版，接受調查的國家中有一半以上 (53%) 部分或完全中斷了高血壓護理和 31% 的心血管急救服務。 COVID-19 的出現迫使政府和公司投入數十億美元進行研發，以便為世界各地的患者帶來更好的治療、藥物和服務。 例如，已發現 COVID-19 會增加所有類型心血管疾病的風險。 根據美國國家生物技術信息中心的數據，2021 年，在 COVID-19 患者中，急性心力衰竭 (3%-33%)、心肌缺血或梗塞 (0.9-11%)、心律失常 (9-17%)、等。觀察到急性心髒病發展的證據。 在大流行期間，該國觀察到的心血管死亡人數有所增加。 例如，根據美國心髒病學會的報告，紐約在大流行期間死於缺血性心髒病 (139%) 和高血壓疾病 (164%) 的相對增幅最高。

心臟安全服務市場的增長主要是由於心血管疾病患病率上升以及人們對心臟問題和慢性心髒病的認識不斷提高。 根據美國國家生物技術信息中心的數據，到 2021 年，全球將有約 6430 萬人患有心力衰竭。 美國的心力衰竭患病率為 600 萬，佔總人口的 1.8%。 在加拿大，患病率在 1.5% 到 1.9% 之間，而在歐洲，美國心臟協會的一份報告估計 2021 年心力衰竭的患病率在 1% 到 2% 之間。 此外，醫療保健行業研發支出的增加和研發活動的外包也是推動市場增長的因素。 現代技術帶來了幫助監測和改善心血管健康的解決方案。 例如，心髒病學和放射學儀器現在使用人工智能和機器來幫助定位潛在的心臟和血管問題，供心髒病專家檢查。 由於人口中心血管疾病的增加，發達國家正趨向於增加對心臟安全服務的利用。

然而，巨大的服務成本和熟練工人的短缺可能會阻礙市場增長。

心臟安全服務的市場趨勢

ECG Holter 測量服務領域主導市場

ECG Holter 測量服務預計將在預測期內主導市場。

該細分市場的增長主要是由於人口老齡化加劇和心血管疾病患病率上升。 Health System Tracker 2022 發布的數據證實，心髒病是美國的頭號死因。 世界心臟聯合會預測，到 2030 年，每年將有超過 2300 萬例與 CVD 相關的死亡。 這些因素推動了對連續心率監測和即時心率檢測設備的需求。 在過去的幾年中，心電圖監測設備已被用於醫療保健系統，以檢測心臟功能異常。 隨著技術的進步，新的 ECG Holter 測量設備正在推出。 Holter 監視器是一種便攜式、電池供電的心電圖設備，患者佩戴 24 至 48 小時，以連續記錄心臟活動（心電圖）並監測心跳。 與傳統心電圖儀相比，這種便攜式心電圖儀具有引線更少、患者在日常生活中可以自由活動等優點。 各種可穿戴心電圖儀已進入市場，包括 Apple Watch、AliveCor 的 KardiaBand 和 Withings 的 ScanWatch，其中包括用於監測心臟健康的心電圖傳感器。 Apple Watch 4 及更高版本以及 AliveCor 的 Kardia 設備都經過美國食品和藥物管理局的測試和批准，可以檢測心房顫動，房顫會導致心力衰竭、中風甚至癡呆。

這些先進的 ECG-Holter 測量設備為心臟安全服務市場的增長提供了有利可圖的機會。

北美主導市場，預計在預測期內也會如此

由於老年患者數量不斷增加且心血管疾病患病率高，預計在預測期內北美將佔心臟安全服務的主要份額。 美國心臟協會公佈的數據（2020）發現，美國每年記錄大約 605,000 例新發心髒病和 200,000 例復發性心髒病發作。 COVID-19 正在增加人們患心髒病的風險。 例如，接受 COVID-19 治療的美國退伍軍人在 12 個月後患心力衰竭的風險增加了 72%。 根據 2022 年版 Nature Medicine 發表的題為“Long Covid may worse heart disease risk”的數據，美國有 1.7% 的 Covid-19 患者患有心血管疾病或心律異常。研究發現，有 2.39% 的患者容易出現血管中形成血栓。

此外，先進的醫療保健系統、提高公眾對心血管疾病預防而非治療的認識、醫療保健運動以及政府對醫療保健系統的投資和服務交付都為該地區的市場增長做出了貢獻。人們認為它正在推動 美國擁有幾家主要監測公司和各種形式的長期心臟監測的主要參與者，包括 Applied Cardiac Systems (ACS) 和通過收購 Spacelabs 成立的 BioTelemetry。

心臟安全服務市場競爭分析

心臟安全服務市場高度分散，參與者眾多。 主要參與者正在使用各種策略，例如新產品發布、擴張、協議、合資企業、合作夥伴關係和收購，以增加他們在這個市場的足跡。 該市場的主要參與者包括 Biotrial、Banook Group、Bioclinica、BioTelemetry、Ncardia AG。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 心血管疾病患病率增加
    • 越來越關注個性化藥物的開發
    • 製藥公司在分析和開發方面的投資增加
  • 市場製約因素
    • 心臟安全性評估的高成本
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 類型
    • 綜合服務
    • 獨立服務
  • 服務類型
    • 心電圖/動態心電圖測量
    • 血壓測量
    • 心血管成像
    • 深入的 QT 研究
  • 最終用戶
    • 製藥和生物製藥公司
    • 簽約研發組織
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Biotrial
    • Bioclinica
    • Ncardia AG
    • Richmond Pharmacology
    • PhysioStim
    • BioTelemetry

第7章 市場機會今後動向

簡介目錄
Product Code: 72610

The cardiac safety service market is expected to register a CAGR of 9% during the forecast period (2022-2027).

The COVID-19 pandemic has imposed a high burden on the healthcare industry, increasing its focus on providing better healthcare facilities, monitoring devices, services, and teleconsultation. According to the World Health Organization, 2020, more than half (53%) of the countries surveyed have partially or completely disrupted services for hypertension treatment and 31% for cardiovascular emergencies. The emergence of COVID-19 has compelled the government and companies to invest a huge amount of money in research and development to provide better treatments, drugs, and services to patients globally. For instance, it has been found that COVID-19 has increased the risk of all types of cardiovascular ailments. According to the National Center for Biotechnology Information, 2021, evidence of acute cardiac compromise was observed in COVID-19 patients, which includes acute heart failure (3%-33%), myocardial ischemia or infarction (0.9%-11%), and arrhythmias (9%-17%). There has been an increased number of cardiovascular deaths observed in the country during the pandemic. For instance, New York experienced the largest relative increase in deaths due to ischemic heart disease (139%) and hypertensive diseases (164%) during the pandemic, as reported by the American College of Cardiology.

The growth of the cardiac safety service market is mainly due to the rising prevalence of cardiovascular diseases and growing awareness among people regarding cardiac problems and chronic heart diseases. According to the National Center for Biotechnology Information, 2021, around 64.3 million people are suffering from heart failure worldwide. The prevalence rate of heart failure in United States is 6 million, which is 1.8% of its total population. In Canada, the prevalence rate is 1,5% to 1.9%, and in Europe, the prevalence rate of heart failure is estimated to be 1% to 2% in 2021, as reported by the American Heart Association. Additionally, the increasing R&D expenditure by the healthcare industries and outsourcing R&D activities are some factors boosting the growth of the market. Modern technology has brought solutions to help monitor and improve cardiovascular health. For instance, cardiology and radiology equipment now use artificial intelligence and machines, which help by locating potential problems in the heart and blood vessels for the cardiologist to review. The increasing number of cardiovascular diseases among the population tends to increase the use of cardiac safety services in developed countries.

However, the huge cost of services and lack of skilled persons are likely to hinder the market growth.

Cardiac Safety Service Market Trends

The ECG Holter Measurement Service Segment Dominates the Market

The ECG Holter service is expected to dominate the market in the forecast period.

The growth in this segment is mainly attributed to a rise in the geriatric population and the increasing prevalence of cardiovascular diseases. According to the data published by Health System Tracker, 2022, it has been observed that heart disease is the number one leading cause of death in United States. The World Heart Federation has predicted more than 23 million CVD-related deaths per year by 2030. Owing to these factors, there is a need for continuous heart rate monitoring and immediate heartbeat detection devices. ECG monitoring devices have been used in the past years in the healthcare system to detect any abnormality in the functioning of the heart. With the advancement of technology, new ECG Holter measurement devices have been introduced. A Holter monitor is a battery-operated portable ECG device that can be worn by a patient for a duration of 24 to 48 hours and records heart activity (electrocardiogram) continuously and monitors the heart rhythm. This portable device provides several advantages over the traditional ECG devices, such as fewer leads, and the patient is free to move and go around their usual daily routines, which has increased its usage among patients and physicians. Various wearable ECG devices have been introduced in the market that have ECG/EKG sensors to monitor heart health, such as Apple Watch, AliveCor's KardiaBand, and the Withings ScanWatch. The Apple Watch 4 and up and the AliveCor Kardia devices all have been tested and approved by the Food and Drug Administration to detect atrial fibrillation, which is a heart condition that can lead to heart failure, strokes, and even dementia.

These advanced ECG-Holter measurement devices offer a lucrative opportunity for the growth of the cardiac safety services market.

North America Dominates the Market, and It is Expected to do the Same During the Forecast Period

North America is expected to account for a major share of cardiac safety services during the forecast period, owing to the rise in the number of geriatric patients and the high prevalence of cardiovascular diseases. According to the data published by the American Heart Association, 2020, it has been found that approximately 605,000 new heart attack cases and 200,000 recurrent heart attacks have been recorded each year in United States. COVID-19 has increased the risk of heart diseases among people. For instance, US veterans who had COVID-19 faced a 72% higher risk of heart failure after 12 months. According to the data published by Nature Medicine, 2022, titled 'Long Covid' may worsen risk of heart diseases", it has been found that 1.7% of COVID-19 patients in United States are more likely to develop cardiovascular diseases or dysregulated heart rhythm, and 2.39% are likely to have blood clots in the blood vessels.

In addition, the advanced healthcare system, increasing awareness among people of preventive measures for cardiovascular diseases instead of treatment, healthcare campaigns, and government investments in the healthcare system and providing services are likely to boost the growth of the market in the region. There are several leading cardiac event monitoring companies in United States that provide various forms of long-term cardiac monitoring, such as Applied Cardiac Systems (ACS) and BioTelemetry, which are formed from acquisitions of several leading monitoring companies and Spacelabs.

Cardiac Safety Service Market Competitive Analysis

The cardiac safety service market is highly fragmented, with the presence of a large number of players in the market. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions to increase their footprints in this market. Some of the major players of the market include Biotrial, Banook Group, Bioclinica, BioTelemetry, and Ncardia AG.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Prevalence of Cardiovascular Diseases
    • 4.2.2 Rising Focus on Developing Personalized Medicines
    • 4.2.3 Growth in the Analysis and Development Investment in Pharma
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Cardiac Safety Evaluation
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Type
    • 5.1.1 Integrated Services
    • 5.1.2 Stand-alone Services
  • 5.2 Service Type
    • 5.2.1 ECG/Holter Measurement
    • 5.2.2 Blood Pressure Measurement
    • 5.2.3 Cardiovascular Imaging
    • 5.2.4 Thorough QT Studies
  • 5.3 End User
    • 5.3.1 Pharmaceutical and Biopharmaceutical Companies
    • 5.3.2 Contract Research Organizations
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Biotrial
    • 6.1.2 Bioclinica
    • 6.1.3 Ncardia AG
    • 6.1.4 Richmond Pharmacology
    • 6.1.5 PhysioStim
    • 6.1.6 BioTelemetry

7 MARKET OPPORTUNITIES AND FUTURE TRENDS